Jazz Pharmaceuticals PLC Net Income
| JAZZ Stock | USD 166.28 0.03 0.02% |
As of the 16th of February 2026, Jazz Pharmaceuticals retains the Downside Deviation of 1.94, market risk adjusted performance of (0.63), and Risk Adjusted Performance of 0.1054. Jazz Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Jazz Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.2441 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 644.1 M | 676.3 M | |
| Net Loss | -201.7 M | -191.6 M | |
| Net Income From Continuing Ops | 504.1 M | 529.3 M | |
| Net Income Per Share | 8.15 | 8.56 | |
| Net Income Per E B T | 1.08 | 0.88 |
Jazz | Net Income | Build AI portfolio with Jazz Stock |
The evolution of Net Income for Jazz Pharmaceuticals PLC provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Jazz Pharmaceuticals compares to historical norms and industry peers.
Latest Jazz Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Jazz Pharmaceuticals PLC over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Jazz Pharmaceuticals PLC financial statement analysis. It represents the amount of money remaining after all of Jazz Pharmaceuticals PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Jazz Pharmaceuticals' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jazz Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 560.12 M | 10 Years Trend |
|
Net Income |
| Timeline |
Jazz Net Income Regression Statistics
| Arithmetic Mean | 284,069,465 | |
| Coefficient Of Variation | 101.47 | |
| Mean Deviation | 226,824,147 | |
| Median | 329,535,000 | |
| Standard Deviation | 288,237,758 | |
| Sample Variance | 83081T | |
| Range | 1B | |
| R-Value | 0.36 | |
| Mean Square Error | 76872.7T | |
| R-Squared | 0.13 | |
| Significance | 0.15 | |
| Slope | 20,781,635 | |
| Total Sum of Squares | 1329296.1T |
Jazz Net Income History
Other Fundumenentals of Jazz Pharmaceuticals PLC
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Jazz Pharmaceuticals Net Income component correlations
Jazz Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Jazz Pharmaceuticals is extremely important. It helps to project a fair market value of Jazz Stock properly, considering its historical fundamentals such as Net Income. Since Jazz Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Jazz Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Jazz Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jazz Pharmaceuticals. Expected growth trajectory for Jazz significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Jazz Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.193 | Earnings Share (6.15) | Revenue Per Share | Quarterly Revenue Growth 0.067 | Return On Assets |
The market value of Jazz Pharmaceuticals PLC is measured differently than its book value, which is the value of Jazz that is recorded on the company's balance sheet. Investors also form their own opinion of Jazz Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Jazz Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jazz Pharmaceuticals' market value can be influenced by many factors that don't directly affect Jazz Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Jazz Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Jazz Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Jazz Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Jazz Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Jazz Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Jazz Pharmaceuticals.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Jazz Pharmaceuticals on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Jazz Pharmaceuticals PLC or generate 0.0% return on investment in Jazz Pharmaceuticals over 90 days. Jazz Pharmaceuticals is related to or competes with Avidity Biosciences, Caris Life, Madrigal Pharmaceuticals, Abivax SA, Cytokinetics, Halozyme Therapeutics, and Rhythm Pharmaceuticals. Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products ... More
Jazz Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Jazz Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Jazz Pharmaceuticals PLC upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.94 | |||
| Information Ratio | 0.0992 | |||
| Maximum Drawdown | 25.96 | |||
| Value At Risk | (3.14) | |||
| Potential Upside | 3.66 |
Jazz Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Jazz Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Jazz Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Jazz Pharmaceuticals historical prices to predict the future Jazz Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1054 | |||
| Jensen Alpha | 0.4073 | |||
| Total Risk Alpha | 0.1383 | |||
| Sortino Ratio | 0.1611 | |||
| Treynor Ratio | (0.64) |
Jazz Pharmaceuticals February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1054 | |||
| Market Risk Adjusted Performance | (0.63) | |||
| Mean Deviation | 1.63 | |||
| Semi Deviation | 1.53 | |||
| Downside Deviation | 1.94 | |||
| Coefficient Of Variation | 824.0 | |||
| Standard Deviation | 3.15 | |||
| Variance | 9.92 | |||
| Information Ratio | 0.0992 | |||
| Jensen Alpha | 0.4073 | |||
| Total Risk Alpha | 0.1383 | |||
| Sortino Ratio | 0.1611 | |||
| Treynor Ratio | (0.64) | |||
| Maximum Drawdown | 25.96 | |||
| Value At Risk | (3.14) | |||
| Potential Upside | 3.66 | |||
| Downside Variance | 3.76 | |||
| Semi Variance | 2.35 | |||
| Expected Short fall | (1.86) | |||
| Skewness | 4.09 | |||
| Kurtosis | 26.07 |
Jazz Pharmaceuticals PLC Backtested Returns
Jazz Pharmaceuticals PLC holds Efficiency (Sharpe) Ratio of -0.0714, which attests that the entity had a -0.0714 % return per unit of risk over the last 3 months. Jazz Pharmaceuticals PLC exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Jazz Pharmaceuticals' Market Risk Adjusted Performance of (0.63), risk adjusted performance of 0.1054, and Downside Deviation of 1.94 to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of -0.59, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Jazz Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Jazz Pharmaceuticals is likely to outperform the market. At this point, Jazz Pharmaceuticals PLC has a negative expected return of -0.12%. Please make sure to check out Jazz Pharmaceuticals' treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to decide if Jazz Pharmaceuticals PLC performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.17 |
Insignificant reverse predictability
Jazz Pharmaceuticals PLC has insignificant reverse predictability. Overlapping area represents the amount of predictability between Jazz Pharmaceuticals time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Jazz Pharmaceuticals PLC price movement. The serial correlation of -0.17 indicates that over 17.0% of current Jazz Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.17 | |
| Spearman Rank Test | 0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 10.23 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Jazz Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Jazz Pharmaceuticals PLC reported net income of 560.12 M. This is 64.12% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 1.9% higher than that of the company.
Jazz Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jazz Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics of similar companies.Jazz Pharmaceuticals is currently under evaluation in net income category among its peers.
Jazz Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Jazz Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Jazz Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Jazz Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Jazz Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Jazz Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Jazz Pharmaceuticals' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 1.2 M | Swedbank Ab | 2025-06-30 | 1.1 M | Bank Of America Corp | 2025-06-30 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 965.7 K | Renaissance Technologies Corp | 2025-06-30 | 900.4 K | Perpetual Ltd | 2025-06-30 | 887.6 K | Aqr Capital Management Llc | 2025-06-30 | 794.8 K | Gmt Capital Corp | 2025-06-30 | 768.4 K | Pacer Advisors, Inc. | 2025-06-30 | 734.6 K | Vanguard Group Inc | 2025-06-30 | 6.1 M | Blackrock Inc | 2025-06-30 | 5.8 M |
Jazz Fundamentals
| Return On Equity | -0.0906 | ||||
| Return On Asset | 0.0488 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 13.49 B | ||||
| Shares Outstanding | 60.77 M | ||||
| Shares Owned By Insiders | 2.97 % | ||||
| Shares Owned By Institutions | 97.01 % | ||||
| Number Of Shares Shorted | 5.66 M | ||||
| Price To Earning | 35.18 X | ||||
| Price To Book | 2.55 X | ||||
| Price To Sales | 2.43 X | ||||
| Revenue | 4.07 B | ||||
| Gross Profit | 3.82 B | ||||
| EBITDA | 1.52 B | ||||
| Net Income | 560.12 M | ||||
| Cash And Equivalents | 899.36 M | ||||
| Cash Per Share | 14.28 X | ||||
| Total Debt | 6.16 B | ||||
| Debt To Equity | 2.12 % | ||||
| Current Ratio | 3.16 X | ||||
| Book Value Per Share | 65.18 X | ||||
| Cash Flow From Operations | 1.4 B | ||||
| Short Ratio | 4.94 X | ||||
| Earnings Per Share | (6.15) X | ||||
| Price To Earnings To Growth | 4.08 X | ||||
| Target Price | 219.4 | ||||
| Number Of Employees | 2.8 K | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 10.11 B | ||||
| Total Asset | 12.01 B | ||||
| Retained Earnings | 1.13 B | ||||
| Working Capital | 3.59 B | ||||
| Current Asset | 1.26 B | ||||
| Current Liabilities | 226.64 M | ||||
| Net Asset | 12.01 B |
About Jazz Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jazz Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.